Oral Antiplatelet Therapy in Coronary Disease

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Ischemic heart disease is a leading global cause of mortality.
• Platelet activation and aggregation are critical targets for therapeutic intervention.
• Current antiplatelet therapies include cyclooxygenase inhibitors and thienopyridines.

Purpose of the Study:

• To review recent literature and guidelines on oral antiplatelet agents for coronary disease management.
• To compare the efficacy and mechanisms of novel antiplatelet agents.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of clinical guidelines and pharmacological data.
• Comparison of antiplatelet agent classes and specific drugs.

Main Results:

• Prasugrel, a novel thienopyridine, provides irreversible P2Y12 receptor inhibition with rapid onset.
• Ticagrelor, a cyclopentyl-triazolo-pyrimidine, offers reversible P2Y12 inhibition with fast and consistent action.
• Both prasugrel and ticagrelor represent advancements over older antiplatelet agents.

Conclusions:

• Novel oral antiplatelet agents, including prasugrel and ticagrelor, offer improved therapeutic profiles for ischemic heart disease.
• These agents provide faster and more consistent platelet inhibition compared to previous treatments.
• Understanding their mechanisms and guidelines is crucial for effective coronary disease management.